SEC Form 4 · accession 0001179110-16-017751
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn E Falberg
Director
Period of report
Jan 13, 2016
Accepted (ET)
Jan 14, 2016 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 13, 2016 | M | 10,000 | $10.37 | A | 328,051 | D | |
| Common Stock | Jan 13, 2016 | M | 10,000 | $4.94 | A | 338,051 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $10.37 | Jan 13, 2016 | M | 10,000 | D | — | May 15, 2017 | Common Stock | 10,000 | 0 | D |
| Options to Purchase Common StockF1 | $4.94 | Jan 13, 2016 | M | 10,000 | D | — | May 8, 2018 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1This option grant became fully vested on the date immediately preceding the date of the company's annual meeting following the date of grant.
Remarks
Exhibit List: Ex. 24 - Power of Attorney